No Data
No Data
Guizhou Yibai Pharmaceutical (600594.SH): first repurchase of 0.34% of company shares.
On July 10th, Gelonhui reported that Guizhou Yibai Pharmaceutical (600594.SH) announced its first repurchase of 2.7239 million shares of the company's stock through a centralized bidding trading method, accounting for 0.34% of the total share capital of the company. The highest and lowest repurchase prices were 2.95 yuan/share and 2.89 yuan/share respectively, and a total amount of RMB 7.9996 million (excluding transaction fees such as commissions) has been paid.
Guizhou Yibai Pharmaceutical Co., Ltd.'s performance forecast for the first half of 2024
Guizhou Yibai Pharmaceutical (600594.SH): expected pre-loss of 100 million yuan to 125 million yuan in the first half of the year.
Guizhou Yibai Pharmaceutical (600594.SH) announced its performance forecast for the first half of 2024. According to the initial calculation of the company's financial department, the company is expected to achieve a net income attributable to the owner of the parent company of -0.125 billion to -0.1 billion yuan in the first half of 2024, with a loss compared to the same period last year. The company expects to achieve a net income attributable to the owner of the parent company after deducting non-recurring gains and losses of -0.131 billion to -0.105 billion yuan in the first half of 2024.
Guizhou Yibai Pharmaceutical (600594.SH): Has not yet implemented share repurchases.
As of June 30, 2024, Guizhou Yibai Pharmaceutical (600594.SH) has not yet started implementing share buybacks, according to the announcement by the company on July 2nd, on Glon Hui website.
Yibai Pharmaceutical (600594.SH) plans to pay 0.066 yuan per share in 2023, excluding interest on June 7
Yibai Pharmaceutical (600594.SH) announced that the company plans to distribute a cash dividend of 0.066 per share in 2023...
Yibai Pharmaceutical (600594.SH): The product Eddy Injection was removed from the Guangdong Union's centralized procurement status of proprietary Chinese medicines such as Qingkailing
Gelonghui, May 17丨Yibai Pharmaceutical (600594.SH) announced that recently, the Guangdong Drug Trade Center issued the “Notice on Cancelling the Status of Guizhou Yibai Pharmaceutical Co., Ltd. Product Eddy Injection” to cancel the selection/alternative status of Guizhou Yibai Pharmaceutical Co., Ltd. product Eddy Injection in Guangdong according to the “Guangdong Alliance Qingkailing and Other Proprietary Chinese Medicines Centralized Volume Procurement Document (GDYJYPDL202103)” on “selected/alternative products suspended production, sales, use, import, etc. by the drug administration department”. Alliance concentrates on proprietary Chinese medicines such as Qingkailing
No Data